#  Ocugen Expands Focus on Inherited Retinal Disorders by Licensing Novel Modifier Gene Therapy Platform 

 





December 20, 2017

 

 

 Ocugen, Inc. has obtained an exclusive worldwide license to develop and commercialize future ophthalmology products based on groundbreaking technology developed by **[Neena Haider, PhD](/neenahaider)**, Associate Professor of Ophthalmology. [Learn about this technology and read the full press release.](http://markets.businessinsider.com/news/stocks/Ocugen-Expands-Focus-on-Inherited-Retinal-Disorders-by-Licensing-Novel-Modifier-Gene-Therapy-Platform-1011680761)



 

 

 



 

 See also:- [ Faculty ](/news-categories/faculty)
- [ Neena Haider, PhD ](/news-categories/neenahaider)
- [ Gene Therapy ](/news-categories/gene-therapy)
- [ Press Release ](/news-categories/press-release)
- [ Retina ](/news-categories/retina)
 
 

 Share on:- [     Facebook ](#)
- [     Twitter ](#)
- [     Linkedin ](#)